BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk
- Author(s):
- Spurdle, A.B.; Whiley, P.J.; Thompson, B.; Feng, B.J.; Healey, S.; Brown, M.A.; Pettigrew, C.; Asperen, C.J. van (0000-0002-1436-7650); Ausems, M.G.E.M.; Kattentidt-Mouravieva, A.A.; Ouweland, A.M.W. van den; Lindblom, A.; Pigg, M.H.; Schmutzler, R.K.; Engel, C.; Meindl, A.; Caputo, S.; Sinilnikova, O.M.; Lidereau, R.; Couch, F.J.; Guidugli, L.; Hansen, T.V.; Thomassen, M.; Eccles, D.M.; Tucker, K.; Benitez, J.; Domchek, S.M.; Toland, A.E.; Rensburg, E.J. van; Wappenschmidt, B.; Borg, A.; Vreeswijk, M.P.G. (0000-0003-4068-9271); Goldgar, D.E.; KConFab; Dutch Belgium UV Consortium; German Consortium Hereditary; French COVAR Grp Collaborators; ENIGMA Consortium
- Published
- 2012
- Publication type
- Article / Letter to editor
- Date issued
- 2012-08-31
- Language
- English
- Is part of
- Journal of Medical Genetics (2012), Vol. 49, no. 8, p. 525-532
- hdl
- 1887/97505
- doi
- 10.1136/jmedgenet-2012-101037